Status: Recruiting
SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)
This placebo-controlled, randomized, blinded, two-arm phase II study will test the safety and potential efficacy of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID.
Participants needed: 100
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Nancy KlimasUpdated: Aug 5, 2025Locations: 1
Eligibility criteria
18 to 70 years old, [+7]
Known active acute SARS-CoV-2 infection ≤ 4 weeks from consent. [+43]